{"filing":{"accession_number":"0001279569-26-000875","cik":"0001702123","ticker":"CRDL","company_name":"Cardiol Therapeutics Inc.","form":"6-K","filing_date":"2026-09-10","report_date":"2026-09-10","primary_document":"cardiol6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1702123/000127956926000875/cardiol6k.htm"},"events":[{"id":32736,"run_id":30097,"accession_number":"0001279569-26-000875","anchor_item_number":"EX-99.1","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"Cardiol Therapeutics announced the filing of a US$150 million preliminary base shelf prospectus with Canadian securities regulators and a corresponding Form F-10 registration statement with the SEC. The shelf prospectus permits the company to offer and sell Class A common shares, debt securities, warrants, subscription receipts, units, or combinations thereof up to US$150 million over 25 months. While the announcement explicitly states \"no securities are being offered\" and \"there can be no assurance that any securities will be offered,\" the filing of a shelf prospectus establishing a US$150 million capacity for future debt and equity issuances is a material capital-raising event that would affect investor assessment of the company's financing plans and potential dilution.","company_name":"Cardiol Therapeutics Inc.","ticker":"CRDL","filing_date":"2026-09-10","form":"6-K","submitted_at":null,"items":[{"id":35987,"accession_number":"0001279569-26-000875","item_number":"EX-99.1","item_title":"ex991.htm","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Cardiol Therapeutics announced the filing of a US$150 million preliminary base shelf prospectus with Canadian securities regulators and a corresponding Form F-10 registration statement with the SEC. The shelf prospectus permits the company to offer and sell Class A common shares, debt securities, warrants, subscription receipts, units, or combinations thereof up to US$150 million over 25 months. While the announcement explicitly states \"no securities are being offered\" and \"there can be no assurance that any securities will be offered,\" the filing of a shelf prospectus establishing a US$150 million capacity for future debt and equity issuances is a material capital-raising event that would affect investor assessment of the company's financing plans and potential dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-10T21:13:41.602137+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35987,"accession_number":"0001279569-26-000875","item_number":"EX-99.1","item_title":"ex991.htm","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Cardiol Therapeutics announced the filing of a US$150 million preliminary base shelf prospectus with Canadian securities regulators and a corresponding Form F-10 registration statement with the SEC. The shelf prospectus permits the company to offer and sell Class A common shares, debt securities, warrants, subscription receipts, units, or combinations thereof up to US$150 million over 25 months. While the announcement explicitly states \"no securities are being offered\" and \"there can be no assurance that any securities will be offered,\" the filing of a shelf prospectus establishing a US$150 million capacity for future debt and equity issuances is a material capital-raising event that would affect investor assessment of the company's financing plans and potential dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-10T21:13:41.602137+00:00","company_name":"Cardiol Therapeutics Inc.","ticker":"CRDL","filing_date":"2026-09-10"}]}